$455.10 Million in Sales Expected for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Quarter

Wall Street brokerages expect BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to report $455.10 million in sales for the current quarter, according to Zacks. Nine analysts have provided estimates for BioMarin Pharmaceutical’s earnings, with the lowest sales estimate coming in at $432.69 million and the highest estimate coming in at $482.30 million. BioMarin Pharmaceutical posted sales of $391.71 million during the same quarter last year, which suggests a positive year over year growth rate of 16.2%. The business is expected to report its next quarterly earnings report on Thursday, October 24th.

On average, analysts expect that BioMarin Pharmaceutical will report full-year sales of $1.70 billion for the current year, with estimates ranging from $1.68 billion to $1.72 billion. For the next fiscal year, analysts expect that the firm will report sales of $1.97 billion, with estimates ranging from $1.82 billion to $2.10 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover BioMarin Pharmaceutical.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.16). BioMarin Pharmaceutical had a negative net margin of 7.19% and a negative return on equity of 3.12%. The company had revenue of $388.00 million during the quarter, compared to analyst estimates of $415.03 million. During the same period in the previous year, the company earned ($0.09) EPS. The company’s quarterly revenue was up 4.0% compared to the same quarter last year.

A number of research analysts have commented on the stock. Wedbush reaffirmed an “outperform” rating and issued a $128.00 target price on shares of BioMarin Pharmaceutical in a research report on Wednesday, July 10th. Robert W. Baird set a $120.00 price target on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a research report on Friday, April 26th. TheStreet cut shares of BioMarin Pharmaceutical from a “c-” rating to a “d+” rating in a research report on Tuesday, May 7th. Citigroup reissued a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Thursday, May 23rd. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $131.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, April 26th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $115.60.

NASDAQ BMRN traded up $4.77 during trading hours on Thursday, reaching $76.50. The company had a trading volume of 1,825,500 shares, compared to its average volume of 1,207,601. The stock has a 50-day moving average of $80.43 and a 200 day moving average of $86.40. BioMarin Pharmaceutical has a 1-year low of $71.53 and a 1-year high of $106.74. The company has a current ratio of 4.11, a quick ratio of 2.79 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $12.87 billion, a P/E ratio of -231.82 and a beta of 1.35.

In other news, Director V Bryan Lawlis sold 3,750 shares of the stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $81.08, for a total transaction of $304,050.00. Following the sale, the director now owns 27,340 shares of the company’s stock, valued at $2,216,727.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.90% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. BB&T Securities LLC raised its holdings in BioMarin Pharmaceutical by 4.0% in the second quarter. BB&T Securities LLC now owns 3,447 shares of the biotechnology company’s stock valued at $295,000 after acquiring an additional 132 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. raised its holdings in BioMarin Pharmaceutical by 0.5% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 27,142 shares of the biotechnology company’s stock valued at $2,411,000 after acquiring an additional 144 shares in the last quarter. Berman Capital Advisors LLC raised its holdings in BioMarin Pharmaceutical by 56.8% in the first quarter. Berman Capital Advisors LLC now owns 417 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 151 shares in the last quarter. Avestar Capital LLC raised its holdings in BioMarin Pharmaceutical by 36.9% in the second quarter. Avestar Capital LLC now owns 750 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 202 shares in the last quarter. Finally, First Mercantile Trust Co. raised its holdings in BioMarin Pharmaceutical by 2.6% in the second quarter. First Mercantile Trust Co. now owns 8,116 shares of the biotechnology company’s stock valued at $695,000 after acquiring an additional 206 shares in the last quarter. 96.86% of the stock is currently owned by hedge funds and other institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Recommended Story: What is the 52-week high/low?

Get a free copy of the Zacks research report on BioMarin Pharmaceutical (BMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.